-
Precise timing of audiovisual stimulation conquers chemobrain Trends Cancer (IF 18.4) Pub Date : 2024-04-21 Lindsey C. Mehl, Erin M. Gibson
In a recent study, Kim et al. utilized gamma entrainment using sensory stimuli (GENUS) to rescue cognitive impairment and glial dysregulation associated with cisplatin and methotrexate chemotherapy, specifically when applied both throughout and after chemotherapy administration. GENUS provides a time-dependent, non-invasive method for treating chemobrain, with broader implications for resolving neurodegenerative
-
Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development Trends Cancer (IF 18.4) Pub Date : 2024-04-09 Tadahito Yasuda, Y. Alan Wang
Although immunotherapy has revolutionized solid tumor treatment, durable responses in gastric cancer (GC) remain limited. The heterogeneous tumor microenvironment (TME) facilitates immune evasion, contributing to resistance to conventional and immune therapies. Recent studies have highlighted how specific TME components in GC acquire immune escape capabilities through cancer-specific factors. Understanding
-
-
-
The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations Trends Cancer (IF 18.4) Pub Date : 2024-04-06 Matthew J. Hadfield, David J. Benjamin, Jonathan Krell, Jeremy Warner, Mark P. Lythgoe
Immune checkpoint inhibitors (ICIs) have transformed cancer care. Recently, atezolizumab gained its first global approval in a subcutaneous (SC) formulation by the UK medicines regulator, being notable as the first time an FDA- and/or European Medicines Agency (EMA)-approved ICI has been licensed via this administration route. Here, we discuss this approval, other SC ICIs in development, and the benefits
-
A big step for MYC-targeted therapies Trends Cancer (IF 18.4) Pub Date : 2024-04-05 Danielle F. Atibalentja, Anja Deutzmann, Dean W. Felsher
The MYC proto-oncogene encodes a master transcriptional regulator that is frequently dysregulated in human cancer. Decades of efforts have failed to identify a MYC-targeted therapeutic, and this is still considered to be a holy grail in drug development. We highlight a recent report by Garralda et al. of a Phase 1 clinical trial of OMO-103 in patients with solid malignancies.
-
Label-free optical imaging for brain cancer assessment Trends Cancer (IF 18.4) Pub Date : 2024-04-04 Raksha Raghunathan, Matthew Vasquez, Katherine Zhang, Hong Zhao, Stephen T.C. Wong
Advances in label-free optical imaging offer a promising avenue for brain cancer assessment, providing high-resolution, real-time insights without the need for radiation or exogeneous agents. These cost-effective and intricately detailed techniques overcome the limitations inherent in magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) scans by offering
-
Exploiting the metabolic vulnerability of circulating tumour cells Trends Cancer (IF 18.4) Pub Date : 2024-04-04 Munise Merteroglu, Massimo M. Santoro
Metastasis has a major part in the severity of disease and lethality of cancer. Circulating tumour cells (CTCs) represent a reservoir of metastatic precursors in circulation, most of which cannot survive due to hostile conditions in the bloodstream. Surviving cells colonise a secondary site based on a combination of physical, metabolic, and oxidative stress protection states required for that environment
-
Nanomedicine to aid immunogenic cell death (ICD)-based anticancer therapy Trends Cancer (IF 18.4) Pub Date : 2024-03-29 Robin Demuynck, Yanou Engelen, André G. Skirtach, Stefaan C. De Smedt, Ine Lentacker, Dmitri V. Krysko
Immunogenic cell death (ICD) is emerging as a key component of antitumor therapy that harnesses the immune system of the patient to combat cancer. In recent years, several efforts were made to improve the ICD-based therapies. Here, we discuss how nanomaterial-based strategies increase the efficacy of ICD and highlight their benefits and challenges.
-
The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatments Trends Cancer (IF 18.4) Pub Date : 2024-03-22 Victoria C. Rayson, Michael A. Harris, Peter Savas, Michael L. Hun, Balaji Virassamy, Roberto Salgado, Sherene Loi
Triple-negative breast cancers (TNBCs) exhibit heightened T cell infiltration, contributing to an enhanced response to immune checkpoint blockade (ICB) compared with other subtypes. An immune-rich immune microenvironment correlates with improved prognosis in early and advanced TNBC. Combination chemotherapy and ICB is now the standard of care in early- and late-stage TNBC. Although programmed death
-
Modulating β-catenin homeostasis for cancer therapy Trends Cancer (IF 18.4) Pub Date : 2024-03-22 Yu Xu, Ying Yu, Rong Yan, Xisong Ke, Yi Qu
β-Catenin is a well-established driver of many cancers; however, there are challenges in developing agents targeting β-catenin for clinical use. Recent progress has indicated that most of the pathological changes in β-catenin may be commonly caused by loss of protein homeostasis. Modulation of β-catenin homeostasis, especially by hyperactivation of β-catenin, potentially leads to robust antitumor outcomes
-
Poised epigenetic states dictate metastatic fitness Trends Cancer (IF 18.4) Pub Date : 2024-03-22 Rebeka Tomasin, Cyrus M. Ghajar
Seeking to define early events that regulate disseminated tumor cell (DTC) fate upon their arrival to the lung, Jakab et al. reach the surprising conclusion that dormancy is determined by a cell autonomous poised epigenetic state that renders DTCs responsive to angiocrine Wnt signaling.
-
Emerging roles of TBK1 in cancer immunobiology Trends Cancer (IF 18.4) Pub Date : 2024-03-21 Alex Miranda, Carl A. Shirley, Russell W. Jenkins
TANK-binding kinase 1 (TBK1) is a versatile serine/threonine protein kinase with established roles in innate immunity, metabolism, autophagy, cell death, and inflammation. While best known for its role in regulating innate immunity, TBK1 has emerged as a cancer cell-intrinsic immune evasion gene by virtue of its role in modulating cellular responses to inflammatory signals emanating from the immune
-
Puzzling phenomenon: adult-onset cancer predisposition and pediatric cancer Trends Cancer (IF 18.4) Pub Date : 2024-03-19 Michaela Kuhlen, Thomas G. Hofmann, Monika M. Golas
Pathogenic variants (PVs) in DNA repair–linked adult-onset cancer predisposition genes, including double heterozygosity, are increasingly identified in pediatric patients with cancer. Their role in childhood cancer, however, remains poorly understood. Integrating comprehensive tumor analysis is integral for understanding the contribution of such PVs in cancer development and personalized cancer care
-
Insights into LINE-1 reverse transcription guide therapy development Trends Cancer (IF 18.4) Pub Date : 2024-03-18 Nicholas M. Zehrbach, Nakyung Oh, Charles A. Ishak
Subsets of long interspersed nuclear element 1 (LINE-1) retrotransposons can ‘retrotranspose’ throughout the human genome at a cost to host cell fitness, as observed in some cancers. Pharmacological inhibition of LINE-1 retrotransposition requires a comprehensive understanding of the LINE-1 ORF2p reverse transcriptase. Two recent publications, by Thawani et al. and Baldwin et al., report structures
-
Tumor immune escape by autotaxin: keeping eosinophils at bay Trends Cancer (IF 18.4) Pub Date : 2024-03-16 Elisa Matas-Rico, Wouter H. Moolenaar
Secreted autotaxin (ATX) promotes tumor progression by producing the pleiotropic lipid mediator lysophosphatidic acid (LPA). In a recent Nature Cancer paper, Bhattacharyya et al. show that ATX/LPA signaling suppresses CCL11-driven infiltration of eosinophils into the pancreatic tumor microenvironment to facilitate tumor progression, thus revealing a new ATX-mediated immune escape mechanism and highlighting
-
Into the era of mycobiome-driven cancer research Trends Cancer (IF 18.4) Pub Date : 2024-03-16 Weici Liu, Zheshun Pi, Ning-Ning Liu, Wenjun Mao
The cancer mycobiome has recently become a research hotspot. While the intratumor mycobiota is implicated in cancer initiation and progression, the gut mycobiota functions as biomarkers for cancer diagnosis and treatment. In this forum article we highlight the involvement of the mycobiome in correlation-, causation-, and prediction-oriented cancer research and discuss the potential of this burgeoning
-
Limited dsRNA editing impedes leukemia stem cells Trends Cancer (IF 18.4) Pub Date : 2024-03-07 Yi Pan, XunLei Kang
Understanding the mechanisms underlying the generation and maintenance of leukemia stem cells (LSCs) is crucial for the development of effective therapies against T cell acute lymphoblastic leukemia (T-ALL). In a recent study, Rivera et al. discovered that elevated adenosine deaminase acting on RNA (ADAR)-1-mediated RNA editing is a distinguishing feature of T-ALL relapse, and that ADAR1 suppresses
-
KMT2C and KMT2D aberrations in breast cancer Trends Cancer (IF 18.4) Pub Date : 2024-03-07 Emily Tinsley, Philip Bredin, Sinead Toomey, Bryan T. Hennessy, Simon J. Furney
KMT2C and KMT2D are histone lysine methyltransferases responsible for the monomethylation of histone 3 lysine 4 (H3K4) residues at gene enhancer sites. KMT2C/D are the most frequently mutated histone methyltransferases (HMTs) in breast cancer, occurring at frequencies of 10–20% collectively. Frequent damaging and truncating somatic mutations indicate a tumour-suppressive role of KMT2C/D in breast oncogenesis
-
Persisting cancer cells are different from bacterial persisters Trends Cancer (IF 18.4) Pub Date : 2024-03-01 Morgane Decollogny, Sven Rottenberg
The persistence of drug-sensitive tumors poses a significant challenge in cancer treatment. The concept of bacterial persisters, which are a subpopulation of bacteria that survive lethal antibiotic doses, is frequently used to compare to residual disease in cancer. Here, we explore drug tolerance of cancer cells and bacteria. We highlight the fact that bacteria, in contrast to cancer cells, have been
-
Tumor-resident microbes: the new kids on the microenvironment block Trends Cancer (IF 18.4) Pub Date : 2024-02-22 Le Li, Vidhi Chandra, Florencia McAllister
Tumor-resident microbes (TRM) are an integral component of the tumor microenvironment (TME). TRM can influence tumor growth, distant dissemination, and response to therapies by interfering with molecular pathways in tumor cells as well as with other components of the TME. Novel technologies are improving the identification and visualization of cell type-specific microbes in the TME. The mechanisms
-
Many faces, many places: delving deeper into CAF heterogeneity in NSCLC Trends Cancer (IF 18.4) Pub Date : 2024-02-22 Kostas A. Papavassiliou, Christos Adamopoulos, Athanasios G. Papavassiliou
In a recent study published in Cancer Cell, Cords et al. employed multiplexed imaging mass cytometry to analyze cancer-associated fibroblast (CAF) heterogeneity in 1070 NSCLC patients. This work defined good and poor prognostic CAF phenotypes, the latter associated with metastasis and chemoresistance, as well as revealed that CAF spatial location correlates with immune cell infiltration and clinical
-
Fusion genes in pancreatic tumors Trends Cancer (IF 18.4) Pub Date : 2024-02-19 Anastasios Gkountakos, Aatur D. Singhi, C. Benedikt Westphalen, Aldo Scarpa, Claudio Luchini
Gene fusions and rearrangements play a crucial role in tumor biology. They are rare events typically detected in KRAS wild-type (WT) pancreatic tumors. Their identification can inform clinical management by enabling precision oncology, as fusions involving BRAF, FGFR2, RET, NTRK, NRG1, and ALK represent actionable targets in KRAS-WT cancers, and serve diagnostic purposes since fusions involving PRKACA/B
-
Immunogenicity of ferroptosis in cancer: a matter of context? Trends Cancer (IF 18.4) Pub Date : 2024-02-16 Elena Catanzaro, Robin Demuynck, Faye Naessens, Lorenzo Galluzzi, Dmitri V. Krysko
Ferroptosis is a variant of regulated cell death (RCD) elicited by an imbalance of cellular redox homeostasis that culminates with extensive lipid peroxidation and rapid plasma membrane breakdown. Since other necrotic forms of RCD, such as necroptosis, are highly immunogenic, ferroptosis inducers have attracted considerable attention as potential tools to selectively kill malignant cells while eliciting
-
Beyond binary: bridging neutrophil diversity to new therapeutic approaches in NSCLC Trends Cancer (IF 18.4) Pub Date : 2024-02-15 Lena Horvath, Constanze Puschmann, Alexandra Scheiber, Agnieszka Martowicz, Gregor Sturm, Zlatko Trajanoski, Dominik Wolf, Andreas Pircher, Stefan Salcher
Neutrophils represent the most abundant myeloid cell subtype in the non-small-cell lung cancer (NSCLC) tumor microenvironment (TME). By anti- or protumor polarization, they impact multiple aspects of tumor biology and affect sensitivity to conventional therapies and immunotherapies. Single-cell RNA sequencing (scRNA-seq) analyses have unraveled an extensive neutrophil heterogeneity, helping our understanding
-
Immunotherapy for colorectal cancer: insight from inherited genetics Trends Cancer (IF 18.4) Pub Date : 2024-02-14 Nijole Pollock Tjader, Amanda Ewart Toland
Immunotherapy shows efficacy for multiple cancer types and potential for expanded use. However, current immune checkpoint inhibitors (ICIs) are ineffective against microsatellite-stable colorectal cancer (CRC), which is more commonly diagnosed. Immunotherapy strategies for non-responsive CRC, including new targets and new combination therapies, are being tested to address this need. Importantly, a
-
Adaptive inhibition of CGAS signaling by TREX1 Trends Cancer (IF 18.4) Pub Date : 2024-02-13 María Cecilia Lira, Claire Vanpouille-Box, Lorenzo Galluzzi
Mammalian cells react to the accumulation of double-stranded (ds)DNA in the cytosol by secreting antiviral and proinflammatory cytokines, notably type I interferon (IFN). Recent data reported by demonstrate that overactivation of this pathway is prevented by an adaptive feedback mechanism elicited by type I IFN receptors and executed by the exonuclease three prime repair exonuclease 1 (TREX1).
-
-
-
In vivo macrophage engineering as novel therapeutic strategy against liver metastasis Trends Cancer (IF 18.4) Pub Date : 2024-02-13 Marie Laviron, Martin Guilliams
In a recent study, report a novel therapeutic strategy to engineer tumor-associated macrophages (TAMs) by inducing the expression of IFNα in these cells. This approach enables improved antigen presentation and T cell activation, leading to controlled tumor growth in multiple murine models of liver metastasis.
-
Using Drosophila to uncover the role of organismal physiology and the tumor microenvironment in cancer Trends Cancer (IF 18.4) Pub Date : 2024-02-13 Chaitali Khan, Nasser M. Rusan
Cancer metastasis causes over 90% of cancer patient fatalities. Poor prognosis is determined by tumor type, the tumor microenvironment (TME), organ-specific biology, and animal physiology. While model organisms do not fully mimic the complexity of humans, many processes can be studied efficiently owing to the ease of genetic, developmental, and cell biology studies. For decades, Drosophila has been
-
Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology Trends Cancer (IF 18.4) Pub Date : 2024-02-13 Gabriele J. Kembuan, Joanna Y. Kim, Marcela V. Maus, Max Jan
Chimeric antigen receptor (CAR) T cell therapy is a medical breakthrough in the treatment of B cell malignancies. There is intensive focus on developing solid tumor-targeted CAR-T cell therapies. Although clinically approved CAR-T cell therapies target B cell lineage antigens, solid tumor targets include neoantigens and tumor-associated antigens (TAAs) with diverse roles in tumor biology. Multiple
-
Epigenetic underpinnings of tumor-immune dynamics in prostate cancer immune suppression Trends Cancer (IF 18.4) Pub Date : 2024-02-09 Duminduni Hewa Angappulige, Nupam P. Mahajan, Kiran Mahajan
Prostate cancer (PC) is immunosuppressive and refractory to immunotherapy. Infiltration of myeloid-derived suppressor cells (MDSCs) and senescent-like neutrophils and T cell exhaustion are observed in the tumor microenvironment (TME) following androgen receptor (AR) antagonism with antiandrogens or androgen ablation. De novo post-translational acetylation of the AR, HOXB13, and H2A at K609, K13, and
-
Sweet dreams: glycosylation controls tumor cell dormancy Trends Cancer (IF 18.4) Pub Date : 2024-02-03 Erin Bresnahan, Jose Javier Bravo-Cordero
In a recent study in , used therapy-associated breast cancer mouse models as well as dormancy models to identify extracellular matrix (ECM)-related tumor cell-autonomous mechanisms of dormancy in residual tumor cells (RTCs). The study reveals an important role of the glycosylation of proteoglycans in sustaining dormancy and opens the door to leverage this biology to eliminate RTCs and prevent recurrence
-
Benefits and opportunities of the transgenic Oncopig cancer model Trends Cancer (IF 18.4) Pub Date : 2024-01-29 Kirtan Joshi, Bhanu P. Telugu, Randall S. Prather, Jeffrey N. Bryan, Timothy J. Hoffman, Jussuf T. Kaifi, Satyanarayana Rachagani
Cancer remains a leading cause of morbidity and mortality, and a paradigm shift is needed to fundamentally revisit drug development efforts. Pigs share close similarities to humans and may serve as an alternative model. Recently, a transgenic ‘Oncopig’ line has been generated to induce solid tumors with organ specificity, opening the potential of Oncopigs as a platform for developing novel therapeutic
-
Adverse effects of ferroptotic therapy: mechanisms and management Trends Cancer (IF 18.4) Pub Date : 2024-01-20 Jiao Liu, Rui Kang, Daolin Tang
Ferroptosis, a nonapoptotic form of cell death characterized by iron accumulation and uncontrolled lipid peroxidation, holds promise as a therapeutic approach in cancer treatment, alongside established modalities, such as chemotherapy, immunotherapy, and radiotherapy. However, recent research has raised concerns about its side effects, including damage to immune cells, hematopoietic stem cells, liver
-
Noncanonical translation of circRNAs drive antitumor immunity Trends Cancer (IF 18.4) Pub Date : 2024-01-18 Jiling Feng, Hao Wu, Shengli Li
Identifying tumor-specific antigenic peptides beyond mutational events is essential for developing effective antitumor immunotherapies. In a recent study, Huang et al. identified an immunogenic cryptic peptide encoded by the circular RNA circFAM53B, through integrating mass spectrometry and ribosome sequencing data from breast cancer samples, and demonstrated its antitumor immunogenicity.
-
Bacteria-derived L-lactate fuels cervical cancer chemoradiotherapy resistance Trends Cancer (IF 18.4) Pub Date : 2024-01-18 Christopher D. Johnston, Susan Bullman
Accumulating studies have demonstrated the presence of viable and metabolically active bacterial communities within a range of solid tumor types. However, the precise mechanisms by which these microbes modulate their infected tumor niches or impact patient responses to cancer treatments remain to be elucidated. Recently, Colbert et al. revealed that L-lactate produced by intratumoral Lactobacillus
-
Impact of tissue-agnostic approvals on management of primary brain tumors Trends Cancer (IF 18.4) Pub Date : 2024-01-19 Manmeet S. Ahluwalia, Atulya A. Khosla, Ahmad Ozair, Mohamed A. Gouda, Vivek Subbiah
Novel tissue-agnostic therapeutics targeting driver mutations in tumor cells have been recently approved by FDA, driven by basket trials that have demonstrated their efficacy and safety across diverse tumor histology. However, the relative rarity of primary brain tumors (PBTs) has limited their representation in early trials of tissue-agnostic medications. Thus, consensus continues to evolve regarding
-
-
-
Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands Trends Cancer (IF 18.4) Pub Date : 2023-12-29 Kelly Boelaars, Yvette van Kooyk
Advances in immunotherapy have revolutionized cancer treatment, yet many patients do not show clinical responses. While most immunotherapies target T cells, myeloid cells are the most abundant cell type in solid tumors and are key orchestrators of the immunosuppressive tumor microenvironment (TME), hampering effective T cell responses. Therefore, unraveling the immune suppressive pathways within myeloid
-
Nonepithelial cancer dissemination: specificities and challenges Trends Cancer (IF 18.4) Pub Date : 2023-12-22 Serena Diazzi, Julien Ablain
Epithelial cancers have served as a paradigm to study tumor dissemination but recent data have highlighted significant differences with nonepithelial cancers. Here, we review the current knowledge on nonepithelial tumor dissemination, drawing examples from the latest developments in melanoma, glioma, and sarcoma research. We underscore the importance of the reactivation of developmental processes during
-
Metabolic interplay: tumor macrophages and regulatory T cells Trends Cancer (IF 18.4) Pub Date : 2023-12-22 Stefania Vilbois, Yingxi Xu, Ping-Chih Ho
The tumor microenvironment (TME) contains a complex cellular ecosystem where cancer, stromal, vascular, and immune cells interact. Macrophages and regulatory T cells (Tregs) are critical not only for maintaining immunological homeostasis and tumor growth but also for monitoring the functional states of other immune cells. Emerging evidence reveals that metabolic changes in macrophages and Tregs significantly
-
Harnessing CD8 T cell responses using PD-1–IL-2 combination therapy Trends Cancer (IF 18.4) Pub Date : 2023-12-20 Masao Hashimoto, Suresh S. Ramalingam, Rafi Ahmed
There is considerable interest in developing more effective programmed cell death (PD)-1 combination therapies against cancer. One major obstacle to these efforts is a dysfunctional/exhausted state of CD8 T cells, which PD-1 monotherapy is not able to overcome. Recent studies have highlighted that PD-1+ T cell factor (TCF)-1+ stem-like CD8 T cells are not fate locked into the exhaustion program and
-
Beyond probiotics: postbiotics sensitize cancer cells to immune checkpoint inhibitors Trends Cancer (IF 18.4) Pub Date : 2023-12-14 Weici Liu, Zheshun Pi, Wenjun Mao
Accumulated research corroborates the feasibility of microbial antitumor therapies, enriching the diversity of cancer therapeutics. Recently, Ferrari et al. revealed the role of postbiotics in sensitizing cancer cells to immune checkpoint inhibitors (ICIs) and synergizing immunotherapy. Particularly, phytosphingosine induces upstream MYD88/NF-κB and downstream NLRC5 activation, enhances T cell effector
-
It’s all about the base: stromal cells are central orchestrators of metastasis Trends Cancer (IF 18.4) Pub Date : 2023-12-09 Lea Monteran, Yael Zait, Neta Erez
The tumor microenvironment (TME) is an integral part of tumors and plays a central role in all stages of carcinogenesis and progression. Each organ has a unique and heterogeneous microenvironment, which affects the ability of disseminated cells to grow in the new and sometimes hostile metastatic niche. Resident stromal cells, such as fibroblasts, osteoblasts, and astrocytes, are essential culprits
-
Plastic persisters: revival stem cells in colorectal cancer Trends Cancer (IF 18.4) Pub Date : 2023-12-08 C, h, r, i, s, t, o, p, h, e, r, , J, ., , T, a, p, e
Colorectal cancer (CRC) is traditionally considered to be a genetically driven disease. However, nongenetic plasticity has recently emerged as a major driver of tumour initiation, metastasis, and therapy response in CRC. Central to these processes is a recently discovered cell type, the revival colonic stem cell (revCSC). In contrast to traditional proliferative CSCs (proCSCs), revCSCs prioritise survival
-
Targeting HER2 heterogeneity in breast and gastrointestinal cancers Trends Cancer (IF 18.4) Pub Date : 2023-11-25 Carmine Valenza, Lorenzo Guidi, Elena Battaiotto, Dario Trapani, Andrea Sartore Bianchi, Salvatore Siena, Giuseppe Curigliano
About 20% of breast and gastric cancers and 3% of colorectal carcinomas overexpress the human epidermal growth factor receptor 2 (HER2) and are sensitive to HER2-directed agents. The expression of HER2 may differ within the same tumoral lesion (spatial intralesional heterogeneity), from different tumor locations (spatial interlesional heterogeneity), and throughout treatments (temporal heterogeneity)
-
-
-
Learning from circadian rhythm to transform cancer prevention, prognosis, and survivorship care Trends Cancer (IF 18.4) Pub Date : 2023-11-23 Xiaoyan Zhu, Geraldine Maier, Satchidananda Panda
Circadian timekeeping mechanisms and cell cycle regulation share thematic biological principles in responding to signals, repairing cellular damage, coordinating metabolism, and allocating cellular resources for optimal function. Recent studies show interactions between cell cycle regulators and circadian clock components, offering insights into potential cancer treatment approaches. Understanding
-
Big data and artificial intelligence in cancer research Trends Cancer (IF 18.4) Pub Date : 2023-11-15 Xifeng Wu, Wenyuan Li, Huakang Tu
The field of oncology has witnessed an extraordinary surge in the application of big data and artificial intelligence (AI). AI development has made multiscale and multimodal data fusion and analysis possible. A new era of extracting information from complex big data is rapidly evolving. However, challenges related to efficient data curation, in-depth analysis, and utilization remain. We provide a comprehensive
-
Targeting immunogenic cell death for glioma immunotherapy Trends Cancer (IF 18.4) Pub Date : 2023-11-14 Tatiana A. Mishchenko, Victoria D. Turubanova, Ekaterina N. Gorshkova, Olga Krysko, Maria V. Vedunova, Dmitri V. Krysko
Immunogenic cell death (ICD) arouses great interest in targeting glioma, the most common primary brain tumor, to achieve boosted immunotherapy. We discuss the unexpected findings on the induction of Th17 immunity by ICD and propose the best design for dendritic cell (DC)-based vaccines loaded with whole glioma lysates obtained after ICD inducers.
-
Affecting change as a clinical academic Trends Cancer (IF 18.4) Pub Date : 2023-11-10 Georgina V. Long, Jennifer Durante, Matthew Browne, Richard A. Scolyer
Clinical academics can effectively advocate for cultural and policy transformations to improve health outcomes; but where do you begin? We present a case study of academics from Melanoma Institute Australia (MIA) who are engaging with the public, media, and policymakers to affect meaningful change in melanoma skin cancer.
-
Successfully targeting the cancer system with metronomics for medulloblastoma Trends Cancer (IF 18.4) Pub Date : 2023-11-07 Nicolas André, Simon Bailey, Andreas Peyrl
The prognosis of the patients with medulloblastoma who relapse after initial treatment including radiotherapy remains dismal. A recent study by Peyrl et al. in JAMA Oncology suggests that the metronomic multidrug combination used in the medulloblastoma European multitarget metronomic antiangiogenic trial (MEMMAT) given at relapse can improve long-term survival.
-
Reductive stress in cancer: coming out of the shadows Trends Cancer (IF 18.4) Pub Date : 2023-11-02 Maolin Ge, Thales Papagiannakopoulos, Liron Bar-Peled
Redox imbalance is defined by disruption in oxidative and reductive pathways and has a central role in cancer initiation, development, and treatment. Although redox imbalance has traditionally been characterized by high levels of oxidative stress, emerging evidence suggests that an overly reductive environment is just as detrimental to cancer proliferation. Reductive stress is defined by heightened
-
Linking ABC transporters to the hallmarks of cancer Trends Cancer (IF 18.4) Pub Date : 2023-10-24 Laurent Duvivier, Louise Gerard, Adriana Diaz, Jean-Pierre Gillet
Human ATP-binding cassette (ABC) transporters are ubiquitously expressed and transport a broad range of endogenous and xenobiotic substrates across extra- and intracellular membranes. Mutations in ABC genes cause 21 monogenic diseases, and polymorphisms in these genes are associated with susceptibility to complex diseases. ABC transporters also play a major role in drug bioavailability, and they mediate
-
Integrating innate and adaptive immunity in oncolytic virus therapy Trends Cancer (IF 18.4) Pub Date : 2023-10-23 Kristin DePeaux, Greg M. Delgoffe
Oncolytic viruses (OVs), viruses engineered to lyse tumor cells, work hand in hand with the immune response. While for decades the field isolated lytic capability and viral spread to increase response to virotherapy, there is now a wealth of research that demonstrates the importance of immunity in the OV mechanism of action. In this review, we will cover how OVs interact with the innate immune system
-
Serrated colorectal cancer: preclinical models and molecular pathways Trends Cancer (IF 18.4) Pub Date : 2023-10-24 Aziz Aiderus, Nick Barker, Vinay Tergaonkar
Serrated lesions are histologically heterogeneous, and detection can be challenging as these lesions have subtle features that may be missed by endoscopy. Furthermore, while approximately 30% of colorectal cancers (CRCs) arise from serrated lesions, only 8–10% of invasive serrated CRCs exhibit serrated morphology at presentation, suggesting potential loss of apparent characteristics with increased